Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Return on Capital Employed for 10 consecutive years, with 0.45% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 34.0% to 0.45% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.45% through Dec 2025, down 34.0% year-over-year, with the annual reading at 0.41% for FY2025, 28.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.45% at Cartesian Therapeutics, down from 0.25% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.2% in Q2 2022, with the low at 0.63% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.2%, with a median of 0.18% recorded in 2021.
  • The sharpest move saw Return on Capital Employed soared 99bps in 2021, then plummeted -74bps in 2023.
  • Over 5 years, Return on Capital Employed stood at 0.05% in 2021, then skyrocketed by 296bps to 0.1% in 2022, then tumbled by -736bps to 0.63% in 2023, then soared by 83bps to 0.1% in 2024, then plummeted by -332bps to 0.45% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.45%, 0.25%, and 0.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.